FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.083,45 +1.839,28 (+3,21%)
BeyondSpring Inc. (BYSI)
Dopo ore:
| Chiusura precedente | 2,2000 |
| Aperto | 2,1800 |
| Denaro | 2,1900 x 100 |
| Lettera | 2,3600 x 100 |
| Min-Max giorno | 2,1800 - 2,3000 |
| Intervallo di 52 settimane | 0,6530 - 4,0000 |
| Volume | |
| Media Volume | 225.248 |
| Capitalizzazione | 87,816M |
| Beta (5 anni mensile) | 0,17 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,5400 |
| Prossima data utili | 06 mag 2024 - 08 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 1,25 |
GlobeNewswireBeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on September 28, 2023, it received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compli
- GlobeNewswire
BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced the presentation of a poster at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place on November 3 through 5
- GlobeNewswire
BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that management will present and participate in the R.W. Baird’s 2023 Global Healthcare Conference, taking place on September 12 to 13, 202
